Additional studies are warranted, particularly among those with severe acne, confirm these results and evaluate the best treatment regimen for further reducing atrophic acne scars.

On subject questionnaire, 83.2% participants reported being "satisfied" or "very satisfied" with study treatment, and 90.2% subjects reported moderate symptomatic improvement.

Although this study is limited by its small sample size, the evidence suggests that oral sarecycline 1.5 mg/kg administered once daily may be a viable treatment option for moderate to severe acne.

An association between impaired QoL in patients with acne and significant psychological problems was consistently noted.

Among the somatic comorbidities evaluated were acne, type 1 diabetes, Down syndrome, hypertension, inflammatory bowel diseases, inflammatory joint diseases, metabolic syndrome, obesity, pilonidal sinus, and thyroid disorders.

Physician-level interventions designed to improve primary adherence with acne medications may have an impact on nonadherence with expensive medications.

The investigators sought to determine the frequency of complications and adverse effects linked to the use of superficial chemical peels in patients with skin types III to VI.

After three months of treatment, patients satisfied with blunt cannula subcision but not Nokor needle subcision.

The study results suggest that hidradenitis suppurativa is both a cutaneous disease and a chronic systemic inflammatory condition.